HCWB HCW Biologics Inc.

HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.

$2.20  +0.05 (2.33%)
As of 06/30/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/20/2021
Outstanding shares:  35,796,457
Average volume:  18,033
Market cap:   $78,752,205
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -38.28
PB ratio:   1.59
PS ratio:   0.00
Return on equity:   -4,164,520.66%
Net income %:   -65.99%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy